Navigation Links
ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
Date:5/20/2008

BUENOS AIRES, Argentina, May 21 /PRNewswire-FirstCall/ -- Today at the World Congress of Cardiology (WCC), the press conference entitled "New Perspectives in Atrial Fibrillation Management" chaired by John Camm, Professor of Clinical Cardiology, St George's University of London, highlighted the importance of the newly announced ATHENA clinical trial results, as the way forward in the future management of Atrial fibrillation, the most common form of cardiac arrhythmia.

To view the Multimedia News Release, please click: http://www.prnewswire.com/mnr/sanofiaventis/33333/

"ATHENA is truly a landmark trial, that marks a paradigm change for the management of atrial fibrillation," said Prof Christopher Cannon, a Senior Investigator in the TIMI Study Group at Brigham and Women's Hospital, Harvard Medical School, who was not involved in the study. "Atrial fibrillation is a very common disease, and our prior treatment options have been focused only on symptom relief and a hope to not do harm, which has been the problem with prior antiarrhythmic drugs. Now, with a highly significant reduction in cardiovascular hospitalisation or death, as well as a 45% reduction in arrhythmic death or 30% cardiovascular death, dronedarone may become a first line treatment of atrial fibrillation."

The ATHENA study results were presented by Prof Stefan Hohnloser last week (15th May 08) at the Heart Rhythm Society's 29th Annual Scientific Sessions in San Francisco, USA. The study results show that dronedarone significantly decreased the risk of cardiovascular hospitalisations or death from any cause by 24% (p=0.00000002), meeting the study's primary endpoint. Results of the primary endpoint were consistent across all the pre-specified clinically relevant subgroups.

The most frequently reported adverse events of Multaq(R) vs. placebo in the ATHENA trial were gastro-intestinal effects (
'/>"/>

SOURCE Sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
2. Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientifics SpyGlass(R) Direct Visualization System
3. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
4. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
5. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
8. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
9. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
10. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
11. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... YORK and VIENNA , July ... at a press conference in New York ... PD01A, a vaccine against Parkinson,s disease. PD01A is the first ... to enter clinical testing. The Michael J. Fox ... $ 1.5 million grant, and presented at the press conference ...
(Date:7/31/2014)... AUSTIN, Texas , July 31, 2014 Vermillion, ... cancers and women,s health, will hold a conference call on ... discuss results for the second quarter ended June 30, 2014. ... to the call. Vermillion,s Chairman, President and CEO ... a question and answer period. Date: Thursday, August ...
(Date:7/31/2014)... July 31, 2014 The Galien Foundation today ... Galien USA Awards. The Prix ... and recognizes the technical, scientific and clinical research skills ... This year brings the highest number of nominees since ... . Nominees include biomedical products across three categories ...
Breaking Medicine Technology:First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 2The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 3The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 4The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology" 5
... HEIGHTS, Ill., Nov. 1, 2011 When it comes to ... and determine the best course of treatment depends on the ... Palos Community Hospital offers patients the most advanced technology in ... is one of only two PEM scanners in the Chicagoland ...
... 1, 2011 Custom Spine unveils its new auxiliary connector ... an extension to the company,s ISSYS LP pedicle screw system, ... screw to be fully seated while maintaining full polyaxial motion ... is unique in its ability to accept multiple rod sizes ...
Cached Medicine Technology:Palos Offers New Technology in the Fight Against Breast Cancer 2Custom Spine Features Unique Auxiliary Connector System at NASS 2
(Date:7/31/2014)... Joseph M. Lee, M.D., M.S., R.P.V.I, ... a leading provider of quality cardiovascular and internal medicine ... Dr. Lee is a board certified cardiologist with a ... addition to his position at CDHV, Dr. Lee is ... Columbia University Medical Center. Dr. Lee is board certified ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Women in ... take charge of their financial future. The Independent ... has opened registration for 6 upcoming Los Angeles area ... for women, and with input from Kim Kiyosaki, a ... It’s Rising Time) who is passionate about women’s financial ...
(Date:7/31/2014)... steadily in the U.S in recent years. According to ... number of individuals reporting past year heroin use almost ... suggests the increase may be linked to prescription opioid ... use to heroin use, with POs providing the entryway ... This drug-use trajectory appears to have become increasingly common ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Clifton Dental ... the application of topical fluoride treatments to their adult ... and help with tooth sensitivity in patients that exhibit ... an infection that is commonly known as “tooth decay” ... tissues of the teeth. , Fluoride therapy ...
(Date:7/31/2014)... Reinberg HealthDay Reporter THURSDAY, ... rather than war experiences, are a source of drinking problems ... study suggests. Setbacks such as job loss, divorce and ... make as many as 13 percent of vets turn to ... has an important effect on mental health in the short ...
Breaking Medicine News(10 mins):Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 2Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 3Health News:The Independent Woman to Offer Financial Workshops in the Los Angeles Area - Developed by Women for Women 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 3Health News:NJ Top Dentists Approved, Clifton Dental Associates Now Actively Recommending the Application of Topical Fluoride Treatments to Adults 2Health News:Civilian Life, Not Combat, May Drive Many Veterans to Drink 2Health News:Civilian Life, Not Combat, May Drive Many Veterans to Drink 3
... Americans with muscular dystrophy die 10 to 12 years younger ... Sept. 14 issue of Neurology , the medical journal ... gap, which was calculated on the basis of 20 years ... annals of research into racial disparities in health care, say ...
... Colorado at Boulder study sheds light on the brain mechanisms ... helpful in improving treatments for the millions of people who ... study, CU-Boulder psychology Professor Yuko Munakata and her research colleagues ... nerve cell suppresses activity in another, is a critical aspect ...
... National Hispanic Science Network on Drug Abuse awarded the ... Investigator to Alice Cepeda, sociology professor and associate director ... Graduate College of Social Work, University of Houston. ... annual conference in New Orleans. , The National ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, ... levels of thimerosal, a mercury-laden preservative that used to be ... autism than infants exposed to only a little thimerosal, new ... who worry that vaccination raises their children,s risk for autism, ...
... 13 (HealthDay News) -- Women can be vulnerable to ... part of a condition called preeclampsia. And now ... which women are most prone to preeclampsia in late ... relies on so-called "metabolic profiling" to track telltale metabolites ...
... mental aging reveals a good news-bad news situation. The bad ... to varying degrees. The good news is the drops are ... study published by the American Psychological Association. "There ... called crystallized intelligence decline at older ages," said study author ...
Cached Medicine News:Health News:Blacks with muscular dystrophy die 10-12 years younger than whites: New study 2Health News:CU-Boulder study sheds light on how our brains get tripped up when we're anxious 2Health News:CU-Boulder study sheds light on how our brains get tripped up when we're anxious 3Health News:University of Houston researcher receives National Award of Excellence in Research 2Health News:More Evidence That Vaccines Don't Cause Autism 2Health News:More Evidence That Vaccines Don't Cause Autism 3Health News:Test Might Spot Women at High Risk for Pregnancy Complication 2Health News:Test Might Spot Women at High Risk for Pregnancy Complication 3Health News:New study reconciles conflicting data on mental aging 2Health News:New study reconciles conflicting data on mental aging 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: